Manulife Partners with Guardant Health to Exclusively Offer Access to Multi‑Cancer Detection Test for Customers in Hong Kong
Single blood test screens for cancer signals across 10 cancer types, supporting earlier detection as part of Manulife’s focus on heathier longevity
For Immediate Release
May 20, 2026
Hong Kong — Manulife Hong Kong today announced a new collaboration with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, to provide eligible customers1 with access to the Multi Cancer Detection (MCD) laboratory developed test (LDT)2 offered by Guardant Health as part of an exclusive regional partnership. Manulife Hong Kong is the city’s first and only insurer to provide customers with access to the MCD test.
Spanning Hong Kong, the Philippines and Singapore, the regional partnership underscores Manulife’s commitment to supporting longer, healthier lives through proactive health management and holistic well being.
The MCD test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)3. With just a blood draw, the MCD test screens for 10 cancer types4.
“Cancer can have a profound impact not only on physical health, but also on families’ long term financial and emotional well being,” said Danny Lee, Chief Health Officer of Manulife Hong Kong and Macau. “By facilitating access to the MCD test through this exclusive partnership, we are giving customers access to innovative screening technologies that support earlier awareness and more informed health decisions. This reflects our broader commitment to helping people live longer, healthier and more financially secure lives — not only through providing financial protection, but by supporting physical well being and longevity at every stage of life.”
Cancer remains one of the most pressing health challenges in Hong Kong. It has consistently been the leading cause of death in Hong Kong, with around 97 people diagnosed with cancer every day5. Early detection is widely recognized as a critical factor in improving treatment outcomes and survival rates6, underscoring the importance of expanding access to innovative screening solutions.
“We are excited to further our partnership with Manulife by introducing the MCD test to their customers in Hong Kong,” said Simranjit Singh, Chief Executive Officer of Guardant Health AMEA. “By reducing barriers to cancer screening with just a blood draw, MCD has the potential to address the growing burden of cancer in Hong Kong. This collaboration reflects our shared commitment to providing access to innovative health solutions, and we look forward to the positive impact we can make together.”
Access to the MCD test will be available to eligible Manulife customers who purchase selected insurance plans1, subject to applicable eligibility criteria, terms and conditions.
To support customers throughout their health journey, Manulife Hong Kong provides follow-up support through its dedicated Case Management Team after the MCD test—reinforcing Manulife’s role as a trusted, long term health partner.
The launch of the MCD test complements Manulife’s broader efforts to advance health innovation and preventive care, supported by insights, innovation, advocacy and investment from the Manulife Longevity Institute, which focuses on research and education around longevity, healthy aging and financial resilience. Through data driven insights and partnerships, the Institute helps shape solutions that address the evolving health and longevity needs of customers in Hong Kong.
For more information about the MCD Test and the related customer offer, please visit the webpage.
The content above does not contain the full terms of the policy(ies), and the full terms can be found in the corresponding policy document(s). Before making a purchase, customers should read the policy provisions for the exact terms and conditions that apply to this product. For product details and key product risks, please refer to the product leaflet.
The Multi-Cancer Detection (“MCD”) test and related services are third-party medical screening services provided by Guardant Health Pte. Ltd. (“Guardant Health”) and its appointed service providers (“Service”). Manulife’s role is strictly limited to providing eligible customers with access to the Service and does not constitute medical advice, diagnosis, recommendation, or endorsement. Manulife and its intermediaries do not provide any medical or clinical services, medical advice or medical recommendations, and make no representation or warranty regarding the accuracy, availability, or results of the MCD test. Customers should assess for themselves whether the MCD test is appropriate for their personal circumstances and consult qualified medical professionals before undergoing the tests. Customers are required to fully and truthfully disclose any MCD test results and/or any related medical information during the new business underwriting, policy change applications and claims application processes where such information is requested, in accordance with applicable disclosure obligations. For the important note in relation to the MCD Test, please visit [Important Note].
Photo:
The Multi-Cancer Detection test screens for 10 cancers through a single blood draw, supporting earlier awareness and screening.
1 Terms and conditions apply. For more details, please refer to the campaign leaflet here.
2 Clinical eligibility will be determined by the medical provider with whom the appointment is booked.
3 The US FDA Breakthrough Device designation referenced includes eight cancer types—bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer.*
*Guardant Health. FDA Grants Breakthrough Device Designation to Guardant Healthʼs Multi-Cancer Detection (MCD) Test. Published June 3, 2025. https://investors.guardanthealth.com/press-releases/press-releases/2025/FDA-Grants-Breakthrough-Device-Designation-to-Guardant-Healths-Shield-Multi-Cancer-Detection-MCD-Test/default.aspx
4 The MCD test is intended to detect the following 10 cancers: Lung, Breast, Colorectal, Prostate, Liver (Hepatocellular), Stomach (Gastric), Bladder, Esophageal, Ovarian and Pancreatic.
5 Hong Kong Cancer Registry, Hospital Authority – Overview of Cancer Statistics in Hong Kong.
6 World Health Organization – Promoting cancer early diagnosis
About Manulife Hong Kong and Macau
Manulife Hong Kong has been a trusted name for more than 125 years, while we have served the Macau market for nearly three decades. Since our operations began in Asia in 1897, we have grown into one of the top-tier providers of financial services, offering a diverse range of protection and wealth products and services to over 2.6 million customers in Hong Kong and Macau. We are committed to helping make decisions easier and lives better for our customers.
Manulife Hong Kong and Macau, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited, and Manulife Provident Funds Trust Company Limited. These entities are all subsidiaries of Manulife Financial Corporation.
About Manulife
Manulife Financial Corporation is a leading international financial services provider, headquartered in Toronto, Canada. Anchored in our ambition to be the number one choice for customers, we operate as Manulife across Canada and Asia, and primarily as John Hancock in the United States, providing financial advice, insurance and health solutions for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment solutions, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2025, we had more than 37,000 employees, over 106,000 agents, and thousands of distribution partners, serving over 37 million customers with operations across 25 markets globally. We trade as ‘MFC’ on the Toronto, New York, and Philippine stock exchanges, and under ‘945’ on the Hong Kong stock exchange. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.
About Manulife Longevity Institute
The Manulife Longevity Institute is a global research, thought leadership, innovation, advocacy, and community investment platform to drive action that can help people live longer, healthier, and more financially secure lives. Underpinned by a $350 million signature commitment, its focus is on helping people extend their healthy years, promoting greater financial resilience for all. As a global insurer, retirement plan provider, and asset manager, Manulife is uniquely placed to help lead this change. The Institute’s work will support Manulife’s Impact Agenda strategy by investing in organizations that are growing the longevity economy, convening research collaborations with leading academic institutions and think tanks, and producing thought leadership to advance awareness and action on the issues impacting populations as they age. The Institute will be known as the John Hancock Longevity Institute in the United States. The actions of the Institute will be guided by a Steering Committee of members of Manulife’s Executive and Global Leadership Teams and in partnership with a robust ecosystem of partners and experts who champion longevity across Canada, Asia, and the US. Canada, Asia, and the US. For more information, please visit Manulife.com/Longevity.
© 2002-2026 Manulife (International) Limited